Tanruprubart's BLA submission for GBS sets a regulatory verdict as the pivotal test of Annexon's value, with ANX007's Phase 3 GA readout as a secondary binary

Bull

A complete, accepted BLA filing followed by a positive FDA action would validate the totality of evidence from the controlled and real-world datasets, including the EMA MAA already under review, positioning tanruprubart for commercial launch in a rare neurological indication with no approved targeted therapy. Approval would represent a transformational inflection for Annexon, unlocking a significant addressable market and de-risking the broader complement inhibition platform ahead of the ARCHER II readout.

Bear

The FDA could issue a Refuse to File letter or a Complete Response Letter citing insufficient U.S.-enrolled patient data, given that the BLA relies substantially on the FORWARD trial data generated in European and other non-U.S. centers, which may not satisfy FDA expectations for adequate and well-controlled domestic evidence. Additional failure modes include manufacturing or chemistry, manufacturing, and controls deficiencies, or a benefit-risk determination unfavorable relative to the established standard of care with IVIG and plasma exchange, particularly given GBS's heterogeneous subtypes and variable natural recovery trajectory.